Mesoblast Limited has released a press release.
FDA Approves New Potency Assay for Commercial Ryoncil
Earlier from Mesoblast
- Mesoblast: Annual Report for Fiscal Year Ending June 30, 2026 (Form 20-F)
- Mesoblast Reports Substantial Revenue Growth to US$120M
- Major Milestone Treatment Completed in P3 Trial for CLBP
- Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch